NRx Pharmaceuticals, Inc. (NRXP) Stock Analysis & Investment Frameworks
NRx Pharmaceuticals, Inc. (NRXP) stock analysis on Invetso. Review NRx Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
NRx Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
NRx Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $113.87M
- Revenue: $1.23M
- ROE: 168.68%
- ROIC: -1855.48%
- Dividend Yield: N/A
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes NRx Pharmaceuticals, Inc. (NRXP) across the following frameworks:
- NRx Pharmaceuticals, Inc. 10Y Growth Potential
- NRx Pharmaceuticals, Inc. Scenario Analysis
- NRx Pharmaceuticals, Inc. Risks & Opportunities
- NRx Pharmaceuticals, Inc. Economic Moat
- NRx Pharmaceuticals, Inc. Business Model
- NRx Pharmaceuticals, Inc. Management
- NRx Pharmaceuticals, Inc. SWOT Analysis
- NRx Pharmaceuticals, Inc. Porter's 5 Forces
- NRx Pharmaceuticals, Inc. PESTLE Analysis
- NRx Pharmaceuticals, Inc. ESG Analysis